Table 3 Amount funded and received for health R&D by income group and country, G-FINDER, 2007–2020
From: Rising pharmaceutical innovation in the Global South: a landscape study
Income group/Country | Amount funded (USD) | Amount received (USD) |
|---|---|---|
High income | 49,514,838,988 | 40,849,557,815 |
Low income | 520,803 | 194,517,036 |
 Rwanda | 250,124 | 155,766 |
 Gambia | 112,869 | 40,386,664 |
 Ethiopia | 97, 273 | 8,022,652 |
 Malawi | 0 | 66,878,265 |
 Uganda | 26,993 | 40,228,555 |
Lower middle income | 931,455,043 | 1,236,080,823 |
 India | 921,038,235 | 960,557,650 |
 Egypt | 4,642,225 | 4,999,887 |
 Indonesia | 2,178,064 | 3,785,469 |
 Ghana | 36,884 | 80,936,027 |
 Bangladesh | 0 | 51,355,381 |
 Kenya | 152,415 | 48,922,220 |
Upper middle income | 527,299,949 | 1,150,535,609 |
 Brazil | 228,032,716 | 253,008,026 |
 South Africa | 111,831,640 | 486,540,102 |
 Russia | 41,567,705 | 42,587,120 |
 Colombia | 36,100,113 | 55,066,738 |
 China | 27,030,281 | 87,306,008 |
Unclassified | 10,523,440,761 | 18,066,864,262 |
Grand total | 61,497,555,545 | 61,497,555,545 |